GROWERIQ
13.9.2022 14:06:45 CEST | Business Wire | Press release
GrowerIQ, the leading cannabis enterprise resource planning (ERP) platform, today announced it recently closed an oversubscribed $3 million CAD ($2.3 million USD) seed round. The round was co-led by Golden Section and MaRS IAF, with participation from LAGO, Delbridge, GTM Fund and Gaingels.
Non-cannabis ERP systems don't work for cannabis production, so producers are stuck using Excel or outdated software that do not talk to each other. This makes it hard to gather data for compliance reporting or analysis.
GrowerIQ was founded to help cannabis companies simplify operations, stay compliant and leverage data to improve their bottom line. The company's ERP includes modules for cultivation, manufacturing, warehouse, CRM, orders and quality management.
Launched in 2020, GrowerIQ has become the go-to solution for cannabis businesses of all sizes, with customers in more than a dozen countries. The company has been credited with driving significant operational efficiencies and savings for its customers.
"This funding allows us to heavily invest in our tech and continue building the most comprehensive cannabis management platform on the market," said GrowerIQ founder and CEO, Andrew Wilson. "We're thrilled to have the support of such experienced investors as we grow our business and help more cannabis companies streamline their operations."
"We invest in founders who have subject matter expertise and vision," said Golden Section Executive Director, Andrew Smith. "The company's leadership certainly meets those criteria, as it seeks to solve a major pain point in an emerging industry that will help businesses be more efficient and compliant on a global scale. The impressive customer base and track record of success, coupled with a focus on capital efficiency and product quality, make this a natural fit for our portfolio. We're excited to partner with GrowerIQ as they scale their business and continue innovating."
The MaRS IAF team said, "The GrowerIQ team impressed us with their deep understanding of the customers and market, and how their needs informed the product development. Throughout the process the team continued to execute on their go to market strategy and consistently drive strong growth. It was quite clear that GrowerIQ was solving a very meaningful problem for their customers. It's been great to work with the team and we look forward to being part of the growth journey."
About GrowerIQ
GrowerIQ is the operational backbone ERP that unites the fragmented systems required by cannabis production facilities around the world. The company now powers facilities in more than a dozen countries, and four languages – enabling true seed-to-sale traceability. For information, visit www.groweriq.com.
About Golden Section
Golden Section is a Houston-based venture capital fund started by experienced business software founders that invests in early-stage B2B SaaS companies. The fund aims to partner with founders, pre-seed to post sale, through a differentiated offering to reduce confusion and chaos, augment team expertise, with an emphasis on capital efficiency, balance, and revenue growth. Our mission is to journey together with founders towards their meaningful exit. www.goldensection.com
About MaRS Investment Accelerator Fund
MaRS Investment Accelerator Fund (IAF) is a leading seed stage fund investing in high-potential IT, health, and cleantech companies. IAF has, over a 10-year history, partnered with 150+ founders building world-class companies. www.marsiaf.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220913005435/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom